Search results
- 12.08Add to watchlist+0.57 (+4.95%)At close: Wed. May 29, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Pre-Market Time
- Open11.62High12.90Low11.62
- Mkt Cap12.49MP/E (TTM)N/ADiv & YieldN/A & N/A
- Prev. Close11.5152 Wk. Low3.9552 Wk. High1,130.40
Related stocks
Find the latest Avalo Therapeutics, Inc. (AVTX) stock quote, history, news and other vital information to help you with your stock trading and investing.
- GPRE
Find the latest Green Plains Inc. (GPRE) stock quote,...
- Sustainability
See Avalo Therapeutics, Inc. (AVTX) Environment, Social and...
- Chart
Interactive Chart for Avalo Therapeutics, Inc. (AVTX),...
- Financials
Get the detailed quarterly/annual income statement for Avalo...
- Profile
See the company profile for Avalo Therapeutics, Inc. (AVTX)...
- SEC Filings
Find the latest Avalo Therapeutics, Inc. (AVTX) stock quote,...
- GPRE
Get the latest Avalo Therapeutics, Inc. (AVTX) stock news and headlines to help you in your trading and investing decisions. News. ... Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March ...
People also ask
When will avtx stock trade on the NASDAQ Capital Market?
Does Avalo Therapeutics (avtx) pay a dividend?
When will Avalo develop avtx-009?
Does Avalo convert non-voting preferred stock to common stock?
Get the latest Avalo Therapeutics Inc (AVTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Mar 27, 2024 · Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026. Executed ...
May 22, 2024 · 20.83%. $20.45M. Omni Health Inc. 0.00%. AVTX | Complete Avalo Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
May 22, 2024 · A high-level overview of Avalo Therapeutics, Inc. (AVTX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates. Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE ...